Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02202447 · ClinicalTrials.gov registry record · Phase 1

Phase 1 of EC1169 In Patients With Recurrent MCRPC

A Phase 1 study of Prostate Cancer, sponsored by Endocyte.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
6
Study locations

NCT02202447: Completed Phase 1 study of Prostate Cancer, sponsored by Endocyte.

NCT02202447 is a Phase 1 study of Prostate Cancer that has completed, run by Endocyte. The registered enrollment target is 40 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02202447, a Phase 1 study of Prostate Cancer, has completed, sponsored by Endocyte.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to determine the safety of EC1169 and the best dose to use in humans in future studies. This study will also determine how EC1169 is distributed, broken down, passed and absorbed through your body and how quickly it is eliminated (leaves the body). All patients will receive EC1169. As a secondary objective in Part A: To explore the relationships between baseline PSMA expression (tumor and patient level) as measured by 99mTc-EC0652 scans and the antitumor activity of EC1169. As an exploratory objective in Part B: To assess EC0652 as a predictive biomarker for the efficacy of EC1169 by comparing PSMA-positive and PSMA-negative lesions for response.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG EC1169
  • OTHER EC0652

Study Locations (6)

Arizona

  • Scottsdale Healthcare Clinical Trials at the Virginia G. Piper Cancer Center - Scottsdale

Connecticut

  • Yale Cancer Center - New Haven

Louisiana

  • Tulane Cancer Center - New Orleans

Nevada

  • Comprehensive Cancer Centers of Nevada - Las Vegas

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • South Texas Accelerated Research Therapeutics - San Antonio

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2014-05
Est. Completion 2018-11-29
Phase Phase 1

Sponsor

Endocyte

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02202447

The ClinicalTrials.gov registry entry for NCT02202447 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which EC1169 is the first listed.

NCT02202447 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Connecticut, Louisiana.

Frequently Asked Questions

What is clinical trial NCT02202447 about?

NCT02202447 is a clinical study titled "Phase 1 of EC1169 In Patients With Recurrent MCRPC". The purpose of this study is to determine the safety of EC1169 and the best dose to use in humans in future studies. This study will also determine how EC1169 is distributed, broken down, passed and absorbed through your body and how quickly it is eliminated (leaves the body). All patients will rece...

What is the current status of trial NCT02202447?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-05. Estimated completion is 2018-11-29.

What conditions does trial NCT02202447 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT02202447?

The interventions under investigation include: EC1169 (DRUG), EC0652 (OTHER).

Who is sponsoring clinical trial NCT02202447?

This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02202447 being conducted?

This trial has 6 study locations across Arizona, Connecticut, Louisiana, Nevada, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.